Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Australia
/
Pharmaceuticals & Biotech
/
CSL
CSL
CSL
Falling future P/E is reasonable given consistent average margins growth to date
CH
Chester
Invested
Community Contributor
Published
08 Jan 25
Updated
20 Aug 25
2
Set Fair Value
0
votes
Share
Chester
's Fair Value
AU$285.53
24.1% undervalued
intrinsic discount
20 Aug
AU$216.60
Loading
1Y
-30.0%
7D
-19.9%
Author's Valuation
AU$285.5
24.1% undervalued
intrinsic discount
Chester's Fair Value
View Valuation
Narrative
Updates
1
Shared on
20 Aug 25
Fair value Decreased 4.69%
Updated for the wishlist
Read more
0
votes
Share
Valuator
Company Info
Notes
Chester
's
Fair Value
AU$285.5
24.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
19b
2014
2017
2020
2023
2025
2026
2028
Revenue US$18.8b
Earnings US$3.6b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.22%
Biotech revenue growth rate
11.77%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.58%
Calculation
US$3.58b
Earnings '28
x
30.00x
PE Ratio '28
=
US$107.42b
Market Cap '28
US$107.42b
Market Cap '28
/
484.23m
No. shares '28
=
US$221.85
Share Price '28
US$221.85
Share Price '28
Discounted to 2025 @ 6.43% p.a.
=
US$184.02
Fair Value '25
US$184.02
Fair Value '25
Converted to AUD @ 1.5516 USD/AUD Exchange Rate
=
AU$285.53
Fair Value '25
